Enveric Biosciences ENVB recently announced that research highlighting the Company’s lead compound, EB-003, is being presented at the 7th Neuropsychiatric Drug Summit.
EB-003 is a promising neuroplastogenic and non-hallucinogenic N, N-Dimethyltryptamine (DMT) analog drug candidate that elicited beneficial outcomes in preclinical models of anxiety and depression. The conference is being held at the Hilton Boston Back Bay in Boston, MA on September 24-26, 2024.
